HUP0000232A2 - Immunotherapeutic imides/amides - Google Patents

Immunotherapeutic imides/amides

Info

Publication number
HUP0000232A2
HUP0000232A2 HU0000232A HUP0000232A HUP0000232A2 HU P0000232 A2 HUP0000232 A2 HU P0000232A2 HU 0000232 A HU0000232 A HU 0000232A HU P0000232 A HUP0000232 A HU P0000232A HU P0000232 A2 HUP0000232 A2 HU P0000232A2
Authority
HU
Hungary
Prior art keywords
general formula
amides
immunotherapeutic
imides
akachexia
Prior art date
Application number
HU0000232A
Other languages
Hungarian (hu)
Inventor
George W. Muller
Mary Shire
David I. Stirling
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of HUP0000232A2 publication Critical patent/HUP0000232A2/en
Publication of HUP0000232A3 publication Critical patent/HUP0000232A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1

Abstract

A találmány tárgya új imid/amid -éterek és -alkőhőlők, amelyek az (I)-es általánős képletű vegyületeket főglalják magűkban. Az (I) általánősképletben, R2 jelentése 1-8 szénatőmős alkil, benzil piridil-metilvagy alkőxi-metil, R4 jelentése -CX-, CH2- vagy CH2CX-; ahől Xjelentése őxigénatőm vagy kénatőm; és n értéke 0, 1, 2, vagy 3,amelyek a tűmőrnekrózis-faktőr a citőkininek inhibitőrai, és amelyek akachexia, az endőtőxin-sőkk, az ízületi gyűlladás, az asztma és aretrővírűs-replikáció ellen felhasználható. A találmány megvalósitásifőrmájába tartőzó tipikűsan ilyen vegyület a 3-ftálimidő-3-(3'4'-dimetőxi-fenil) prőpán-1-ől. ŕThe subject of the invention is new imide/amide ethers and alkaloids, which contain compounds of general formula (I) in their cores. In the general formula (I), R2 is C1-C8 alkyl, benzyl pyridylmethyl or alkyloxymethyl, R4 is -CX-, CH2- or CH2CX-; where X means oxygen atom or sulfur atom; and n is 0, 1, 2, or 3, which are inhibitors of the needle marrow necrosis factor cytokinins, and which can be used against akachexia, toxin-related diseases, arthritis, asthma, and herpesvirus replication. Typically such a compound belonging to the embodiment of the invention is from 3-phthalimido-3-(3'4'-dimethoxyphenyl)propan-1. ŕ

HU0000232A 1996-12-03 1997-12-03 Immunotherapeutic imides/amides HUP0000232A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/759,788 US5703098A (en) 1994-12-30 1996-12-03 Immunotherapeutic imides/amides
PCT/US1997/022369 WO1998024763A2 (en) 1996-12-03 1997-12-03 Immunotherapeutic imides/amides as pde iv and tnf inhibitors

Publications (2)

Publication Number Publication Date
HUP0000232A2 true HUP0000232A2 (en) 2000-09-28
HUP0000232A3 HUP0000232A3 (en) 2000-10-30

Family

ID=25056962

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000232A HUP0000232A3 (en) 1996-12-03 1997-12-03 Immunotherapeutic imides/amides

Country Status (13)

Country Link
US (1) US5703098A (en)
EP (1) EP0942902A2 (en)
JP (1) JP2001506611A (en)
KR (1) KR20000069374A (en)
CN (1) CN100372836C (en)
AU (1) AU735540B2 (en)
CA (1) CA2273002A1 (en)
FI (1) FI991187A (en)
HU (1) HUP0000232A3 (en)
NZ (1) NZ336713A (en)
RU (1) RU2177471C2 (en)
SK (1) SK73299A3 (en)
WO (1) WO1998024763A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
EP1361210B1 (en) * 1996-08-12 2008-12-24 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US6309674B1 (en) * 1997-05-21 2001-10-30 Medion Research Laboratories Therapeutic agents for respiratory diseases
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
ES2260043T3 (en) 1999-08-21 2006-11-01 Altana Pharma Ag SYNERGIC COMBINATION OF ROFLUMILAST AND SALMETEROL.
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US8030343B2 (en) 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US7491634B2 (en) * 2006-04-28 2009-02-17 Asm International N.V. Methods for forming roughened surfaces and applications thereof
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
NZ536050A (en) * 2002-04-12 2007-11-30 Celgene Corp Methods of identifying modulators of angiogenesis using stem cells with the proviso the stems cells are not totipotent
US20050118715A1 (en) * 2002-04-12 2005-06-02 Hariri Robert J. Modulation of stem and progenitor cell differentiation, assays, and uses thereof
KR101059041B1 (en) 2002-05-17 2011-08-24 셀진 코포레이션 Methods and compositions for using selective cytokine inhibitory drugs for the treatment and treatment of cancer and other diseases
MXPA05003889A (en) * 2002-10-15 2005-06-22 Celgene Corp Selective cytokine inhibitory drugs for treating myelodysplastic syndrome.
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
MXPA05004777A (en) * 2002-11-06 2005-07-22 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases.
TW200501945A (en) 2002-11-06 2005-01-16 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP1581205A1 (en) * 2002-11-18 2005-10-05 Celgene Corporation Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
BR0316256A (en) * 2002-11-18 2005-10-04 Celgene Corp Methods of inhibiting tnf-alpha production and pde4 activity, treating or preventing a disease or disorder, controlling camp levels in a cell and producing a compound, pharmaceutical composition and compound
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CA2517487A1 (en) * 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
NZ547689A (en) 2003-11-19 2009-05-31 Signal Pharm Llc Indazole compounds and methods of use thereof as protein kinase inhibitors
AU2005234783A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
MX2007005040A (en) * 2004-10-28 2007-06-19 Celgene Corp Methods and compositions using pde4 modulators for treatment and management of central nervous system injury.
CN102036663A (en) * 2008-03-24 2011-04-27 细胞基因公司 Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
PE20151143A1 (en) 2009-02-10 2015-08-07 Celgene Corp METHODS TO USE AND COMPOSITIONS INCLUDING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND CONTROL OF TUBERCULOSIS
MY183201A (en) * 2009-10-09 2021-02-18 Celgene Corp Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds
JP5937060B2 (en) 2010-04-07 2016-06-22 セルジーン コーポレイション Method for treating respiratory viral infections
MX341896B (en) 2010-06-15 2016-09-07 Celgene Corp * Biomarkers for the treatment of psoriasis.
EP2601950A1 (en) * 2011-12-06 2013-06-12 Sanofi Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
WO2015175956A1 (en) 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
ES2749433T3 (en) 2014-06-23 2020-03-20 Celgene Corp Apremilast for the treatment of liver disease or abnormal liver function
WO2017070291A1 (en) 2015-10-21 2017-04-27 Celgene Corporation Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles

Also Published As

Publication number Publication date
NZ336713A (en) 2001-02-23
AU735540B2 (en) 2001-07-12
KR20000069374A (en) 2000-11-25
AU5594598A (en) 1998-06-29
SK73299A3 (en) 1999-12-10
CN1254333A (en) 2000-05-24
EP0942902A2 (en) 1999-09-22
RU2177471C2 (en) 2001-12-27
WO1998024763A2 (en) 1998-06-11
CN100372836C (en) 2008-03-05
CA2273002A1 (en) 1998-06-11
WO1998024763A3 (en) 1998-08-06
FI991187A0 (en) 1999-05-25
FI991187A (en) 1999-07-16
HUP0000232A3 (en) 2000-10-30
US5703098A (en) 1997-12-30
JP2001506611A (en) 2001-05-22

Similar Documents

Publication Publication Date Title
HUP0000232A2 (en) Immunotherapeutic imides/amides
NO180165C (en) Heterocyclic amines useful in the therapy of asthma and inflammation of the respiratory tract
DK0436334T3 (en) 3-Aminopiperidine derivatives and related nitrogen-containing heterocyclic compounds
EA200200208A1 (en) SYNERGY COMPOSITION
DE69331190D1 (en) BRIDGED AZABICYCLIC DERIVATIVES AS SUBSTANCE P ANTAGONISTS
BR9206161A (en) Fluoroalkoxybenzylamino derivatives of nitrogen-containing heterocycles
FI942187A (en) Acyclic ethylenediamine derivatives as substance P-receptor antagonists
NO970163L (en) Use of heterocyclic compounds
HUP0002495A1 (en) Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
NO924310L (en) NEVROP PROTECTIVE INDOLONES AND RELATED DERIVATIVES
ATE244713T1 (en) SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE (PDE) TYPE 4 AND TUMOR NECROSIN FACTOR (TNF)
FI934983A0 (en) Kinuclidine derivatives Foer behandling av inflammatoriska och gastrointestinala sjukdomar
ES2064665T3 (en) IMPROVEMENTS IN AND IN RELATION TO ANGIOTENSIN II ANTAGONISTS.
SE9301241L (en) indole derivatives
PT805158E (en) INHIBITORS OF PROTEIN KINASE C HALOGEN-SUBSTITUTED
NO970161D0 (en) Triazole Compounds and Their Use
ATE234616T1 (en) THIADIAZOLE COMPOUNDS AS D3 DOPAMINE RECEPTOR LIGAND
FR2712591B1 (en) New arylpiperazines derived from indole, their preparation and their therapeutic use.
PE46699A1 (en) INDOL-DERIVED COMPOUND
IE880248L (en) 5-(3-Alkyl-5-tert¹butyl-4-hydroxyphenyl)-2-amino-6h-1,3,4-thiadiazines, a¹process for the preparation thereof, medicaments containing¹same, and the use thereof
DK571786D0 (en) CEPHALOSPORIN DERIVATIVES, PROCEDURES FOR PREPARING IT, AND PHARMACEUTICAL AGENTS CONTAINING THEREOF
ATE217307T1 (en) HETEROCYCLIC SUBSTITUTED PROPENEIC ACID DERIVATIVES AS NMDA ANTAGONISTS
FI880987A (en) 1- (1-ARYL-2-HYDROXIETYL) IMIDAZOLER OCH DERAS SALTER, FOERFARANDE FOER DERAS FRAMSTAELLNING, LAEKEMEDEL INNEHAOLLANDE DESSA FOERENINGAR OCH DERAS ANVAENDNING.
NO993069L (en) New use of dipeptides
DK109786A (en) CONDENSED HETEROCYCLIC COMPOUNDS